Search

Displaying results 5601 - 5610 of 7017 in total
  1. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.

  2. Drug

    CB-010

    go.drugbank.com/drugs/DB17711
    Investigational

    CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.[L46158]

  3. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).

  4. Drug

    Nelonicline

    go.drugbank.com/drugs/DB19040
    Investigational

    Nelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).

  5. Drug

    Rezvilutamide

    go.drugbank.com/drugs/DB19133
    Investigational

    Rezvilutamide is under investigation in clinical trial NCT05956639 (Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in Mhspc).

  6. Drug

    Brenetafusp

    go.drugbank.com/drugs/DB19441
    Investigational

    Brenetafusp is under investigation in clinical trial NCT04262466 (Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors).

    Synonyms: [171-cysteine,189-alanine,203-asparatic acid] ant, Immunoglobulin, anti-(human CD3 antigen ε-chain) (human-Mus musculus single-chain Fv fragment VL-((GGGGS)4GGGS)-VH) fusion protein with peptide linker (GGGGS) fusion protein with T-cell receptor β chain
  7. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  8. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.

  9. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. … CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain.

  10. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.